Treatment of acute promyelocytic leukemia for older patients

Thomas Prebet, Steven D. Gore

Research output: Contribution to journalReview articlepeer-review


Acute promyelocytic leukemia (APL) represents a remarkable disease in which leukemogenesis is driven by the PML-RARα oncogene and for which targeted treatment with all-trans retinoic acid (ATRA)-based therapy allows substantial chance of cure. APL is seen in a small subset of older patients, with age representing one of the most important prognostic factors for outcome of treatment. Unlike other acute leukemias, the inferior outcomes for APL in older patients relates less to changes in disease biology and more to the increased toxicity of ATRA and the chemotherapy combination regimens used to induce hematologic and molecular responses. Risk-adapted strategies that use less-toxic agents, such as arsenic trioxide, allow treatment of older patients, with greater efficiency and better chances of cure.

Original languageEnglish (US)
Pages (from-to)337-342
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number3
StatePublished - Mar 1 2011
Externally publishedYes


  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • Arsenic
  • Older patient

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Treatment of acute promyelocytic leukemia for older patients'. Together they form a unique fingerprint.

Cite this